IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

/0 %	
In re application of: Neeper et al.	Group No.: 1633
U.S. Serial No.: 10/728,131	,
Filed: December 4, 2003	Examiner: Li, Qian Janice
For: SYNTHETIC HUMAN PAPILLOMAVIRUS GENES	I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450,
Commissioner for Patents P.O. Box 1450	Alexandria, Virginia 22313-1450, on the date appearing below.
Alexandria, VA 22313-1450	MERCK & CO., INC. 1 By Hances Col 28 06
TERMINAL DISCLAIMER TO	O OBVIATE)
A DOUBLE PATENTING REJECTION	
[37 CFR 1.321]	
I, Joanne Giesser 126 East Lincoln Avenue, RY60-30, Rahway, NJ 07065	, residing at, am a representative
of the assignee identified below, empowered to act on its Corporate Resolution No. 5, dated 05/11/2006	behalf, pursuant to attached
The assignee, Merck & Co., Inc.	, certifies
that it is the assignee of the entire right, title and interest patent application by virtue of an Assignment from the in patent application, which was	
recorded in the United States Patent & Trademark O Frame(s) 0866 on 08/18/2005	office on Reel(s) <u>016645</u>
was forwarded for recording on, with and assignment attached hereto, or	h a copy of the recordation form
is being concurrently forwarded for recording under recordation form and assignment attached hereto.	separate cover, with a copy of the
The aforesaid assignment establishes the ownership in the application pursuant to 37 CFR 3.73(b).	e assignee of the above-identified
The undersigned has reviewed all of the evidentiary docu above-identified patent application, and the undersigned undersigned's knowledge and belief, title is in the assigned.	ments in the chain of title of the certifies that, to the best of the
I hereby disclaim the terminal part of the statutory term of above-identified application, which would extend beyond statutory term of:	e named above. If any patent granted on the lithe expiration date of the full sently shortened by any terminal sently shortened by any terminal
United States Patent No. 7,001,995 , or as pres disclaimer,	sently shortened by any terminal
Any patent granted on application serial number	

USSN 10/728,131 Case No. 20413YCA

Page 2

and hereby agree that any patent so granted on the above-identified application shall be enforceable on, for and during such periods that the legal title to said patent shall be the same as the legal title to:

544110 til 0110 1100 1100
United States Patent No. 7,001,995,
Any patent granted on application serial number,
this agreement to run with any patent granted on the above-identified application and to be binding upon the grantor, its successors or assigns.
Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of:
United States Patent No. <u>7,001,995</u> , or as presently shortened by any terminal disclaimer,
Any patent granted on application serial number,
in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is otherwise terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.
The Commissioner is requested to charge Account No. 13-2755 the sum of \$130.00 and any fee deficiency required by this paper. A duplicate of this disclaimer is attached.
I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

In Duplicate Attachs.

Date: June 28, 2006

Disclaimant Joanne Giesser
Patent Counsel

Title

Merck & Co., Inc. Patent Dept., RY60-30

P.O. Box 2000

Rahway, New Jersey 07065-0907 Telephone No. (732) 594-3046 MERCK & CO. INC.

CERTIFICATION

I, Debra A. Bollwage, Senior Assistant Secretary of Merck & Co., Inc. (the "Company"), a corporation duly organized and existing under the laws of the State of New Jersey, do hereby certify that the attached, presently in full force and effect, is a true and correct copy of General Corporate Resolution #5, Patent Matters, as amended by Unanimous Written Consent of the Board of Directors of said Company on April 25, 2006.

IN WITNESS WHEREOF, I have hereunto subscribed my signature and affixed the seal of the Company this 11th day of May 2006.

Senior Assistant Secretary

(SEAL)

General Corporate Resolution #5

PATENT MATTERS

RESOLVED, that any of the following:

Richard T. Clark-Chief Executive Officer and President Kenneth C. Frazier-Senior Vice President and General Counsel Joseph F. DiPrima-Vice President and Assistant General Counsel Paul D. Matukaitis-Vice President and Assistant General Counsel William Krovatin-Counsel, IP Litigation Edward W. Murray-Counsel, IP Litigation Charles M. Caruso-Counsel, International Valerie J. Camara-Counsel, Patents Mark R. Daniel-Counsel, Patents Joanne M. Giesser-Counsel, Patents Anthony Rollins-Counsel, European Patents David L. Rose-Counsel, Patents Jack L. Tribble-Counsel, Patents Melvin Winokur-Counsel, Patents Edward M. Yoshida-Counsel, Rosetta Inpharmatics John Oksinski-Executive Director, Banyu Kenji Matsuyama-Director, Banyu Donna L. Margiotto-Senior Manager, Patent Administration

are authorized to execute and to revoke on behalf of Merck & Co., Inc. and its affiliates (including subsidiaries) the following documents relating to patent matters:

Powers of attorney as fully in law as may be necessary and proper in connection with the acquisition, registration, maintenance and enforcement of patents and applications for patents, including powers of attorney relating to the prosecution or defense of patent rights before courts of law or other governmental tribunals, agencies or departments; affidavits and declarations; and any other documents which are necessary and proper for the acquisition, registration, maintenance, litigation and protection of patents.

